Department of Haematology, Hospital Universitario Central de Asturias, Spain.
CHIMOMODepartment, University of Modena and Reggio Emilia, Modena, Italy.
Eur J Cancer. 2021 Nov;157:132-139. doi: 10.1016/j.ejca.2021.08.005. Epub 2021 Sep 8.
Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical course from that of FL that responds to front-line treatments. In addition to having poor responses to salvage therapies, it seems that patients with PREF are at increased risk of histological transformation (HT). The Aristotle consortium presented the opportunity of investigating the risk of HT in a very large series of cases. Thus, we investigated the risk of HT in patients with PREF FL compared with that of responding patients or in stable disease and ultimately their outcome.
Six thousand three hundred thirty-nine patients from the Aristotle database were included in the analysis. These patients had a histologically confirmed grade 1, 2 or 3a FL diagnosed between 1997 and 2013. The primary end-points were the cumulative incidence (CI) of HT at the first progression or relapse and the survival after transformation.
The 5-year CI of HT among patients with PREF was 34% (95% confidence interval (CI): 27-43), whilst it was 7.1% (95% CI: 6.0-8.5) in the group of patients with partial response (PR) or stable disease (SD) (PR + SD) and 3.5% (95% CI: 3.0-4.2) in the group of patients achieving complete response (CR). The 5-year survival after relapse (SAR) was 33% (95% CI: 28-39) for the PREF group, 57% (95% CI 54-61) in patients with PR, 51% (95% CI 43-58) in the SD group after first-line therapy and 63% (95% CI: 66-72) in patients with CR after initial treatment (p-value <0.001). The 5-year SAR for those patients with PREF who developed HT was 21% (95% CI: 12-31), clearly diminished when compared with those patients with PREF who did not experience HT (38% [95% CI: 31-44]) (p-value = 0.001).
Patients with PREF FL have a dismal outcome and an associated very high rate of HT that further worsens their poor prognosis.
原发性难治性(PREF)滤泡性淋巴瘤(FL)的临床病程与对一线治疗有反应的 FL 完全不同。除了对挽救疗法的反应不佳外,似乎 PREF 患者发生组织学转化(HT)的风险增加。Aristotle 联合会提供了在非常大量病例中研究 HT 风险的机会。因此,我们调查了与有反应的患者或稳定疾病患者相比,PREF FL 患者发生 HT 的风险,以及他们的最终结局。
对来自 Aristotle 数据库的 6339 例患者进行了分析。这些患者在 1997 年至 2013 年间经组织学确诊为 1 级、2 级或 3a 级 FL。主要终点是首次进展或复发时 HT 的累积发生率(CI)和转化后的生存。
PREF 患者 5 年 HT 的 CI 为 34%(95%CI:27-43),而部分缓解(PR)或稳定疾病(SD)(PR+SD)患者的 CI 为 7.1%(95%CI:6.0-8.5),完全缓解(CR)患者的 CI 为 3.5%(95%CI:3.0-4.2)。PREF 组患者复发后 5 年的生存率(SAR)为 33%(95%CI:28-39),PR 组为 57%(95%CI 54-61),一线治疗后 SD 组为 51%(95%CI 43-58),初始治疗后 CR 组为 63%(95%CI:66-72)(p 值<0.001)。在发生 HT 的 PREF 患者中,5 年 SAR 为 21%(95%CI:12-31),与未发生 HT 的 PREF 患者(38%[95%CI:31-44])相比明显降低(p 值=0.001)。
PREF FL 患者预后不良,发生 HT 的比例非常高,进一步恶化了其预后不良。